In related news, manufacturer of palonosetron hydrochloride was recently awarded the Drug Shortage Assistance Award from the US FDA,
Palonosetron hydrochloride (Simplist, Fresenius Kabi) is now available in a prefilled injection formulation, according to a recently released media statement. The injection is available in a .25 mg per 5 mL single dose strength.
Palonosetron hydrochloride Injection is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for: moderately emetogenic cancer chemotherapy to prevent acute and delayed nausea and vomiting and highly emetogenic cancer chemotherapy to prevent acute nausea and vomiting associated with initial and repeat courses. It is also indicated to prevent acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy in some pediatric patients.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company was recently awarded the Drug Shortage Assistance Award from the US FDA, which recognized the company’s role in helping to mitigate a shortage of IV saline after Hurricane Maria in 2017.